Clinical trials: Amyloid
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Enpowering Progression Risk of Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical…
- Trial name
- PRIORITY (NCT06960538)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Multiple Myeloma (MM)
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
This study is a prospective, single-center, phase Ib/II clinical trial designed to evaluate the tolerability of sonrotoclax plus dexamethasone in this phase Ib/II umbrella study and to determine the recommended phase II dose…
- Trial name
- AL-005 (NCT07687004)
- Testing
- Sonrotoclax, CM336 (BCMA/CD3 bispecific antibody)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Amyloidosis
A Study of NPT189 in Healthy Subjects
The purpose of the study is to evaluate the safety and tolerability of single dose of NPT189 in healthy volunteers. The study will also evaluate the pharmacokinetic characteristics of NPT189.
- Trial name
- NCT03610035
- Testing
- NPT189
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Proclara Biosciences, Inc.
Amyloidosis
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
Patients with primary systemic amyloidosis will be treated with CC-5013 (lenalidomide; Revlimid) as a single agent for 3 months.
- Trial name
- NCT00166413
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Arterial Disease, Arterial Occlusive Diseases
Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Superficial Femoral Artery
The purpose of this study is to evaluate whether the results of drug eluting balloon are non-inferior to the Nitinol stent implantation in the femoropopliteal segment.
- Conditions
- Peripheral Arterial Disease, Arterial Occlusive Diseases, Atherosclerosis, Arteriosclerosis
- Trial name
- PAVENST (NCT02212470)
- Testing
- Drug Eluting Balloon Angioplasty, Nitinol stenting
- Where
- Brazil
- Volunteers
- 85 people
- Sponsor
- Instituto Dante Pazzanese de Cardiologia
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
- Trial name
- NCT03997383
- Testing
- Patisiran
- Where
- 90 sites in United States, Argentina and 20 more
- Volunteers
- 360 people
- Sponsor
- Alnylam Pharmaceuticals
Frail Elderly
Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults
The current study seeks to examine the prevalence of amyloid pathology, among patients referred to the Toulouse Geriatric Frailty Clinic presenting objective memory impairment.
- Trial name
- COGFRAIL (NCT03129269)
- Testing
- MRI and PET scan
- Where
- France
- Volunteers
- 344 people
- Sponsor
- University Hospital, Toulouse
Cerebral Amyloid Angiopathy
Balance Eyesight and Muscle Tension in the Cervical Spine in Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is one form of disease of the small vessels of the brain and can cause frequent cerebral hemorrhages as well as other types of stroke.
- Trial name
- NCT05082194
- Testing
- balance with open and closed eyes
- Where
- Poland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Anna Olczak
AL Amyloidosis
Radioimmunoimaging of Light Chain (AL) Amyloidosis
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
- Trial name
- NCT01815086
- Testing
- Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Tennessee
Cardiac Amyloidosis, Spinal Stenosis
Prevalence of Cardiac Amyloidosis in Patients Undergoing Surgery for Lumbar Spinal Stenosis.
Patients undergoing surgery for lumbar spinal stenosis will have biopsies of the ligamentum flavum sent to the department of pathology for histologic screening.
- Trial name
- CASS-II (NCT05701397)
- Testing
- DPD scintigraphy
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Steen Hvitfeldt Poulsen
Coronary Artery Disease, Plaque
Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography
Instantaneous wave-free ratio (iFR™) is a novel non-hyperaemic index of the functional significance of a coronary stenosis. Previous studies have shown variable levels of correlation with the established hyperaemic index FFR.
- Conditions
- Coronary Artery Disease, Plaque, Atherosclerosis, Fractional Flow Reserve
- Trial name
- VERIFY2 (NCT02377310)
- Where
- United Kingdom
- Volunteers
- 197 people
- Sponsor
- Golden Jubilee National Hospital
Amyloidosis
Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis
Although the use of bortezomib has reported efficacy in amyloid light chain (AL) amyloidosis, the role of bortezomib with dexamethasone (BD) in the first-line treatment of patients with AL amyloidosis should be determined.
- Trial name
- NCT02485613
- Testing
- bortezominb and dexamethasone
- Volunteers
- 72 people
- Sponsor
- Zhi-Hong Liu, M.D.
Obstructive Coronary Artery Disease, Coronary Artery Disease
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Coronary artery disease (CAD) remains a leading cause of death in most countries. It is well known that the reduction of cholesterol levels by statin therapy is associated with significant decreases in plaque burden.
- Trial name
- NCT01837823
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
ATTR Amyloidosis
The Italian Transthyretin Amyloidosis Web-Network
The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and…
- Trial name
- ITA-WebNet (NCT05444920)
- Where
- 30 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Dementia, Alzheimer Disease
Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid
The early detection of a preclinical AD or early stage of AD with amyloid imaging could improve the diagnosis and provide knowledge for better therapeutical approach by combining the best of imaging: structural MR sequences and…
- Trial name
- NCT02343757
- Testing
- PET/MRI
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University Hospitals Cleveland Medical Center
Non-ischemic Cardiomyopathy, Cardiomyopathies
Cardiovascular Multimodality Imaging Study
Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis.
- Conditions
- Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy
- Trial name
- NCT06610019
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Montefiore Medical Center
Alzheimer Disease
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
- Trial name
- NCT03522129
- Testing
- CT1812
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Cognition Therapeutics
AL Amyloidosis
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
The goal of this clinical trial is to learn if Equecabtagene Autoleucel(Eque-cel), a Chimeric Antigen Receptor T-cell (CAR-T) therapy, works to treat severe Light Chain (AL) Amyloidosis in newly diagnosed adults with Mayo Stage…
- Trial name
- NCT07055724
- Testing
- Eque-cel CAR-T Therapy
- Volunteers
- 17 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Mild Cognitive Impairment
Home-based Cognitive Monitoring in MCI
This study is an observational study to confirm usefulness of a home-based cognitive monitoring in non-demented patients with high-risk of dementia
- Trial name
- NCT04350801
- Testing
- home-based cognitive monitoring
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center